Beta-cell selective KATP-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity

Regulatory Peptides

Volumn 165, Issue 2-3, 2010, Pages 158-162

  Ritzel, Robert A ^a,b,c   Jayasinghe, Sajith ^d   Hansen, John B ^e   Sturis, Jeppe ^e   Langen, Ralf ^f   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Klinikum Schwabing   (Germany)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e NOVO NORDISK A S   (Denmark)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apoptosis; Beta cell; Diabetes; Human islets

Indexed keywords

AMYLIN; POTASSIUM CHANNEL STIMULATING AGENT;

APOPTOSIS; ARTICLE; CELL EXPANSION; CELL PROTECTION; CELL STIMULATION; CELL STRUCTURE; CHANNEL GATING; CONTROLLED STUDY; CYTOTOXICITY; HORMONAL REGULATION; HUMAN; HUMAN CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; WHOLE CELL;

BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIC S-OXIDES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; KATP CHANNELS;

EID: 78649814620     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.06.009     Document Type: Article

References (31)

1. Grill V., Bjorklund A. Overstimulation and beta-cell function. Diabetes 2001, 50:S122-S124.
2. Ritzel R.A., Hansen J.B., Veldhuis J.D., Butler P.C. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11mM) glucose. J Clin Endocrinol Metab 2004, 89:795-805.
3. Ritzel R.A. Therapeutic approaches based on beta-cell mass preservation and/or regeneration. Front Biosci 2009, 14:1835-1850.
4. Laedtke T., Kjems L., Porksen N., Schmitz O., Veldhuis J., Kao P.C., Butler P.C. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol 2000, 279:E520-E528.
5. Maedler K., Spinas G.A., Lehmann R., Sergeev P., Weber M., Fontana A., Kaiser N., Donath M.Y. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001, 50:1683-1690.
6. Weir G.C., Laybutt D.R., Kaneto H., Bonner-Weir S., Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001, 50:S154-S159.
7. Poitout V., Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
8. Wang H., Kouri G., Wollheim C.B. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005, 118:3905-3915. Epub2005 Aug 3909.
9. Clark A., Cooper G.J., Lewis C.E., Morris J.F., Willis A.C., Reid K.B., Turner R.C. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987, 2:231-234.
10. Johnson K.H., O'Brien T.D., Betsholtz C., Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989, 321:513-518.
11. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
12. Janson J., Soeller W.C., Roche P.C., Nelson R.T., Torchia A.J., Kreutter D.K., Butler P.C. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996, 93:7283-7288.
13. Janson J., Ashley R.H., Harrison D., McIntyre S., Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498.
14. Ritzel R.A., Butler P.C. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003, 52:1701-1708.
15. Jayasinghe S.A., Langen R. Membrane interaction of islet amyloid polypeptide. Biochim Biophys Acta 2007, 1768:2002-2009. Epub 2007 Feb 2006.
16. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
17. Ritzel R.A., Meier J.J., Lin C.Y., Veldhuis J.D., Butler P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 2007, 56:65-71.
18. Apostolidou M., Jayasinghe S.A., Langen R. Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding. J Biol Chem 2008, 283:17205-17210. Epub 12008 Apr 17228.
19. Maedler K., Storling J., Sturis J., Zuellig R.A., Spinas G.A., Arkhammar P.O., Mandrup-Poulsen T., Donath M.Y. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004, 53:1706-1713.
20. Yoshikawa H., Ma Z., Bjorklund A., Grill V. Short-term intermittent exposure to diazoxide improves functional performance of beta-cells in a high-glucose environment. Am J Physiol Endocrinol Metab 2004, 287:E1202-E1208. Epub 2004 Aug 1203.
21. Bedrood S., Jayasinghe S., Sieburth D., Chen M., Erbel S., Butler P.C., Langen R., Ritzel R.A. Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity. Biochemistry 2009, 48:10568-10576.
22. Greenwood R.H., Mahler R.F., Hales C.N. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976, 1:444-447.
23. Ortqvist E., Bjork E., Wallensteen M., Ludvigsson J., Aman J., Johansson C., Forsander G., Lindgren F., Berglund L., Bengtsson M., Berne C., Persson B., Karlsson F.A. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diab Care 2004, 27:2191-2197.
24. Guldstrand M., Grill V., Bjorklund A., Lins P.E., Adamson U. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 2002, 28:448-456.
25. Gier B., Krippeit-Drews P., Sheiko T., Aguilar-Bryan L., Bryan J., Dufer M., Drews G. Suppression of KATP chan atic beta cells against oxidative stress. J Clin Invest 2009, 119:3246-3256. Epub 32009 Oct 38811. 10.1172/JCI38817.
26. Skak K., Gotfredsen C.F., Lundsgaard D., Hansen J.B., Sturis J., Markholst H. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 2004, 53:1089-1095.
27. Sargsyan E., Ortsater H., Thorn K., Bergsten P. Diazoxide-induced beta-cell rest reduces endoplasmic reticulum stress in lipotoxic beta-cells. J Endocrinol 2008, 199. 41-50, Electronic publication 2008 Jul 2021.
28. Liu Y., Schubert D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem 1997, 69:2285-2293.
29. Yang A.J., Chandswangbhuvana D., Margol L., Glabe C.G. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 1998, 52:691-698.
30. Hosoi N., Holt M., Sakaba T. Calcium dependence of exo- and endocytotic coupling at a glutamatergic synapse. Neuron 2009, 63:216-229.
31. Huang C.J., Gurlo T., Haataja L., Costes S., Daval M., Ryazantsev S., Wu X., Butler A.E., Butler P.C. Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem 2009, 285:339-348.